Highlights

  • Recce Pharmaceuticals (ASX:RCE) received ethics approval to advance its Australian diabetic foot infection trial to pivotal Phase 3.
  • The study is evaluating R327G, a synthetic topical anti-infective for diabetic foot infections.
  • Trial eligibility has expanded to include mild and moderate infections.
  • Recruitment progress, clinical outcomes and regulatory pathways remain key future milestones.

Recce Pharmaceuticals (ASX:RCE) has advanced its diabetic foot infection program into a pivotal Phase 3 development pathway after receiving ethics approval for a protocol amendment.

The update allows the company to pursue a registration-focused clinical program for R327G Topical Gel, while expanding patient eligibility and continuing international development activities.

However, the program remains in the early recruitment phase, with clinical data required to determine future regulatory and commercial potential.

What Happened?

On 22 June 2026, Recce Pharmaceuticals announced Human Research Ethics Committee (HREC) approval for a protocol amendment that upgrades its Australian diabetic foot infection (DFI) trial to pivotal Phase 3 status.

The trial is evaluating RECCE 327 Topical Gel (R327G), a synthetic anti-infective designed to target difficult-to-treat infections.

The updated protocol expands eligibility to patients with mild and moderate diabetic foot ulcer infections, including infected ulcers below the knee.

The company stated that the revised trial design is intended to support potential registration submissions with regulators.

Why It Matters

Diabetic foot infections are a significant complication of diabetes and can lead to serious outcomes including hospitalisation and amputation.

A key challenge in treating these infections is the increasing prevalence of bacteria resistant to existing antibiotics.

Recce is developing R327G as a potential alternative approach to treating these infections.

The Phase 3 designation is important because it moves the program towards a trial structure intended to generate data suitable for regulatory review.

Expanding eligibility to mild and moderate infections may also increase the potential patient population and support recruitment.

The Numbers

Key trial details include:

  • Australian Phase 3 trial target: approximately 200 patients.
  • Patients enrolled at announcement: 18 participants.
  • Interim analysis trigger: 50% of patients completing the study.
  • Expanded patient group: mild and moderate diabetic foot infections.
  • Addressable proportion: company estimates these cases represent approximately 80% of diabetic foot infection presentations.

Recce is also progressing international commercial discussions.

The company entered a non-binding term sheet for potential exclusive licensing of R327G across 12 countries in the Middle East and North Africa region.

The arrangement remains non-binding and does not represent confirmed revenue.

The Bigger Picture

Recce’s strategy focuses on addressing antimicrobial resistance, an area where treatment Options are becoming increasingly limited.

The company is developing synthetic anti-infective compounds designed to address infections caused by resistant bacteria.

The diabetic foot infection program is being advanced through parallel clinical activities in Australia and Indonesia, with trials designed around United States Food and Drug Administration regulatory standards.

The company’s approach is intended to support potential regulatory pathways across Australia, the United States, MENA markets and ASEAN regions.

The topical gel format may also provide a targeted treatment approach by applying therapy directly to infected areas.

The Bull Case

The positive case for Recce Pharmaceuticals (ASX:RCE) is based on advancing a potential new anti-infective treatment in an area with significant medical need.

Moving the DFI trial to pivotal Phase 3 provides a clearer pathway towards possible regulatory approval.

The expanded trial design increases the potential patient pool and may improve commercial relevance.

International development plans and potential licensing opportunities could broaden future market access if clinical outcomes are successful.

Risks Investors Should Understand

Recce Pharmaceuticals (ASX:RCE)’s Business faces risks including clinical trial outcomes, regulatory uncertainty, funding requirements and commercial execution.

The Phase 3 designation does not guarantee success, and the trial must still demonstrate safety and effectiveness.

With only 18 patients enrolled at the time of the update, meaningful clinical data remains several stages away.

The MENA licensing arrangement is non-binding and may not result in a completed commercial agreement.

As a pre-revenue biotechnology company, Recce may require additional Capital to fund development activities, while operating multiple international studies creates additional execution complexity.

What Comes Next?

The next key milestone is recruitment progress towards the approximately 200-patient Australian trial target.

Investors will monitor progress towards the 50% enrolment milestone that triggers interim analysis.

Further developments around the Indonesian program, regulatory discussions and potential conversion of licensing discussions into formal agreements will also remain important.

Conclusion

Recce Pharmaceuticals (ASX:RCE) has advanced its R327G diabetic foot infection program by moving its Australian study into a pivotal Phase 3 framework.

The milestone expands the trial design and strengthens the company’s pathway towards potential regulatory approval.

However, the program remains at an early stage of recruitment, and the key evidence will come from future clinical results. The Phase 3 designation creates the opportunity, but trial outcomes will determine whether R327G can become a commercial anti-infective product.